| Literature DB >> 24991664 |
Sandeep S Nerkar, Ashok J Tamhankar, Smita U Khedkar, Cecilia Stålsby Lundborg.
Abstract
In many hilly tribal areas of the world, water scarcity is a major problem and diarrhoea is common. Poor quality of water also affects the environment. An integrated watershed management programme (IWMP) aims to increase availability of water and to improve life conditions. Globally, there is a lack of information on water contamination, occurrence of diarrhoea and antibiotic resistance, a serious global concern, in relation to IWMP in hilly tribal areas. Therefore, a prospective observational study was conducted during 2011–2012 in six villages in a hilly tribal belt of India, three with and three without implementation of an IWMP, to explore quality of water, diarrhoeal cases in the community and antibiotic resistance of Escherichia coli from water sources. The results showed that physico-chemical quality of water was within limits of safe consumption in all samples. The odds of coliform contamination in water samples was 2.3 times higher in non-watershed management villages (NWMV) compared to integrated watershed management villages (IWMV) (95% CI 0.8–6.45, p = 0.081). The number of diarrhoeal cases (18/663 vs. 42/639, p < 0.05) was lower in IWMV as compared to NWMV. Overall E. coli isolates showed high susceptibility to antibiotics. Resistance to a wider range of antibiotics was observed in NWMV.Entities:
Mesh:
Year: 2014 PMID: 24991664 PMCID: PMC4078572 DOI: 10.3390/ijerph110606156
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Physico-chemical quality parameters (average/month) of water from each well of six tribal villages with and without implementation of integrated watershed management programme.
| Parameter | Integrated Watershed Management Villages (IWMV) | Non-Watershed Management Villages (NWMV) | |||||
|---|---|---|---|---|---|---|---|
| Water Sources | Water Sources | ||||||
| IWMV1 | IWMV2 | IWMV3 | IWMV4 | NWMV1 | NWMV2 | NWMV3 | |
| pH | 7.2 | 7.2 | 7.1 | 7.2 | 7.1 | 7.2 | 7.3 |
| (7.0–7.3) | (7.0–7.4) | (7.0–7.3) | (7.0–7.4) | (7.0–7.3) | (7.0–7.4) | (7.0–7.4) | |
| Turbidity a (NTU) | 2.5 | 13.7 | 0 | 0.6 | 1.3 | 3.3 | 1.3 |
| (0–5) | (5–25) | (0–5) | (0–5) | (0–10) | (0–5) | ||
| Chloride content b (ppm) | 25 | 22.5 | 20.8 | 20 | 20.8 | 20 | 20 |
| (20–60) | (20–40) | (20–30) | (20–30) | ||||
| Total hardness c (ppm) | 98 | 106 | 79 | 83.3 | 54 | 56 | 81 |
| (50–125) | (75–200) | (50–175) | (75–125) | (50–100) | (50–175) | (50–150) | |
| Nitrate content d (ppm) | 15.8 | 12.3 | 10 | 10 | 10 | 10 | 10 |
| (10–45) | (10–45) | ||||||
Notes: n—Number of samples; According to World Health Organisation (WHO) [18]—Maximum Acceptable Limits (MAcL) and Maximum Allowable Limit (MAlL) are; a MAcL = 5 NTU, MAlL = 25 NTU; b MAcL = 200 ppm, MAlL = 600 ppm; c MAcL = 50 ppm, MAlL = 200 ppm; d MAcL = 10 ppm, MAlL = 45 ppm; figures in parenthesis indicate range. The asterix indicates that there was no variation between the samples. All values are rounded off to the nearest decimal point.
Month-wise coliform count/100 mL water and antibiotic resistance of Escherichia coli isolated from water sources of tribal villages with and without implementation of integrated watershed management programme.
| Month | Integrated Watershed Management Villages (IWMV) | Non-Watershed Management Villages (NWMV) | |||||
|---|---|---|---|---|---|---|---|
| Coliform Count/100 mL | Coliform Count/100 mL | ||||||
| S/R (Resistance to Mentioned Antibiotics) | S/R (Resistance to Mentioned Antibiotics) | ||||||
| Water Sources | Water Sources | ||||||
| IWMV1 | IWMV2 | IWMV3 | IWMV4 | NWMV1 | NWMV2 | NWMV3 | |
| 2011/07 | 170 | 7900 | 0 | 33 | 140 | 41 | 7000 |
|
|
|
|
| ||||
| 2011/08 | 14 | 0 | 0 | 0 | 7.8 | 7.8 | 0 |
|
| |||||||
| 2011/09 | 130 | 22 | 220 | 0 | 0 | 13 | 13000 |
|
|
| ||||||
| 2011/10 | 350 | 240 | 0 | 350 | 0 | 79 | 920 |
|
|
|
|
|
| |||
| 2011/11 | 0 | 7.8 | 280 | 140 | 0 | 11 | 42 |
|
|
|
|
| ||||
| 2011/12 | 0 | 0 | 0 | 0 | 140 | 0 | 130 |
|
| |||||||
| 2012/01 | 0 | 0 | 0 | 33 | 0 | 140 | 280 |
|
|
| ||||||
| 2012/02 | 350 | 0 | 0 | 140 | 0 | 350 | a |
|
|
| ||||||
| 2012/03 | 0 | 0 | 0 | 0 | 0 | 130 | a |
| 2012/04 | 94 | 0 | 0 | a | 0 | 0 | a |
|
| |||||||
| 2012/05 | 0 | 0 | 0 | a | 130 | 0 | a |
| 2012/06 | 0 | 0 | 0 | a | 0 | 0 | a |
| Frequency of contamination (%) | 6/12 | 4/12 | 2/12 | 5/9 | 4/12 | 8/12 | 6/7 |
| (50) | (33) | (17) | (56) | (33) | (67) | (86) | |
Notes: N—Total number of samples; S—Susceptible; R—Resistant; 0—Absence of coliform; a—No sampling; NA—Nalidixic acid (MIC ≥ 32); TE—Tetracycline (MIC ≥ 16); AMP—Ampicillin (MIC ≥ 32); TI—Ticarcillin (MIC ≥ 128); PI—Piperacillin (MIC ≥ 128); PI64—Piperacillin (MIC ≥ 64); NIT—Nitrofurantoin (MIC = 64); CEP—Cephalothin (MIC = 64); COT—Co-trimoxazole (MIC ≥ 320); AT—Aztreonam (MIC = 4); All cephalosporins tested in two AST cards- [Cephalothin (MIC = 64); Cefazolin (MIC ≥ 64); Cefuroxime (MIC ≥ 64); Cefotetan (MIC = 2); Cefuroxime Axetil (MIC ≥ 64); Cefpodoxime (MIC ≥ 8); Cefotaxime (MIC ≥ 64); Ceftizoxime (MIC ≤ 1); Cefepime (MIC = 2)]; ESBL—Extended Spectrum Beta-Lactamases; Unit for MIC values is mg/L.
Data on yearly average antibiotics delivered (DDDs/1,000 inhabitants/year) to sub-centres of Primary Health Centre during the years 2008–2011 and 2011–2012 in tribal villages with and without the implementation of integrated watershed management programme.
| Antibiotic, Assigned DDD | 2008–2011 (June–May) | 2011–2012 (June–May) | ||
|---|---|---|---|---|
| IWMV | NWMV | IWMV | NWMV | |
| Tetracycline, 1 g | 458 | 391 | 302 | 39 |
| Ampicillin, 2 g | 6 | -- | -- | -- |
| Amoxicillin, 1 g | 163 | 33 | 38 | 58 |
| Co-trimoxazole, 2 g | 267 | 225 | 124 | 99 |
| Erythromycin, 1 g | -- | 27 | -- | -- |
| Ciprofloxacin, 1 g | 7 | 52 | -- | -- |
| Norfloxacin, 0.8 g | 75 | 47 | 189 | 156 |
| Nalidixic Acid, 4 g | -- | -- | 1.5 | -- |
| Total DDDs/1,000 inhabitants/year | 976 | 775 | 654 | 352 |
Notes: IWMV—Integrated Watershed Management Villages; NWMV—Non-Watershed Management Villages; DDD—Defined Daily Dose; PHC—Primary Health Center.
Co-resistance and Multi Drug Resistance (MDR) of Escherichia coli from well water of tribal villages with and without the implementation of integrated watershed management programme.
| Resistance | IWMV ( | NWMV ( |
|---|---|---|
| Resistant to one group of antibiotics | 3 (18) | 3 (17) |
| Resistant to two groups of antibiotics (co-resistance) | 2 (11) | 2 (11) |
| Resistant to three or more than three groups of antibiotics (MDR) | 1 (6) | 2 (11) |
| Susceptible to all | 11 (65) | 11 (61) |
Notes: N—Total number of isolates; IWMV—Integrated watershed management villages; NWMV—Non-watershed management villages.
Antibiotic resistance of Escherichia coli isolated from well water in tribal villages with and without the implementation of integrated watershed management programme
| Antibiotics | IWMV ( | NWMV ( |
|---|---|---|
| Tetracycline | 3 | 3 |
| Ampicillin | 1 | 3 |
| Cephalothin (1st) | 1 | 4 |
| Cefuroxime (2nd) | 0 | 1 |
| Cefotaxime (3rd) | 0 | 1 |
| Cefepime (4th) | 0 | 0 |
| Aztreonam | 0 | 1 |
| Meropenam | 0 | 0 |
| Co-trimoxazole | 0 | 2 |
| Amikacin | 0 | 0 |
| Nalidixic acid | 4 | 3 |
| Nitrofurantoin | 1 | 2 |
Notes: IWMV—Integrated Watershed Management Villages; NWMV—Non-Watershed Management Villages; N—Total number of isolates; n—Resistant isolates; 1st—1st generation cephalosporins; 2nd—2nd generation cephalosporins; 3rd—3rd generation cephalnosporins; 4th—4th generation cephalosporins.
List of antibiotics used for susceptibility testing using the Vitek 2 AST (antibiotic susceptibility test) cards.
| Card No.- | AST GN 25 | Card No.- | AST EXN7 |
|---|---|---|---|
| Sr. No | Antimicrobial | Sr. No | Antimicrobial |
| 1 | ESBL | 1 | Amoxicillin/Clavulanic acid |
| 2 | Ampicillin | 2 | Ticarcillin |
| 3 | Ampicillin/Sulbactum | 3 | Ticarcillin/Clavulanic acid |
| 4 | Piperacillin/Tazobactum | 4 | Piperacillin |
| 5 | Cefazolin | 5 | Cephalothin |
| 6 | Cefriaxone | 6 | Cefuroxime |
| 7 | Cefepime | 7 | Cefuroxime Axetil |
| 8 | Aztreonam | 8 | Cefotetan |
| 10 | Imipenam | 10 | Cefotaxime |
| 11 | Meropenem | 11 | Ceftizoxime |
| 12 | Amikacin | 12 | Aztreonam |
| 13 | Gentamicin | 13 | Meropenem |
| 14 | Tobramicin | 14 | Nalidixic Acid |
| 15 | Ciprofloxacin | 15 | Moxifloxacin |
| 16 | Moxifloxacin | 16 | Norfloxacin |
| 17 | Tigecycline | 17 | Tetracycline |
| 18 | Nitrofurantoin | 18 | Tigecycline |
| 19 | Trimethoprim/ Sulfamethoxazole |